Clinical trials: Degenerative Conditions, Neurologic
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Leber Congenital Amaurosis 10, Blindness
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
- Trial name
- HYPERION (NCT06891443)
- Testing
- sepofarsen
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 32 people
- Sponsor
- Laboratoires Thea
Generalized Myasthenia Gravis
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
- Trial name
- ziMyG (NCT06055959)
- Testing
- Zilucoplan
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 8 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease.
- Trial name
- NCT01484990
- Testing
- Levodopa-Carbidopa
- Volunteers
- 19 people
- Sponsor
- AbbVie
Parkinson's Disease
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who…
- Trial name
- ACTIVATE (NCT05819359)
- Testing
- BIA 28-6156 10 mg, BIA 28-6156 60 mg
- Where
- 95 sites in United States, Canada and 9 more
- Volunteers
- 237 people
- Sponsor
- Bial R&D Investments, S.A.
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Amyotrophic Lateral Sclerosis, ALS
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04165850
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Parkinson's Disease
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199420
- Testing
- Istradefylline (KW-6002)
- Where
- 2 sites in United States
- Volunteers
- 580 people
- Sponsor
- Kyowa Kirin, Inc.
Multiple System Atrophy, MSA - Multiple System Atrophy
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
- Trial name
- NCT05698017
- Testing
- hOMSC300
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Cytora Ltd.
Parkinson Disease, Neurodegenerative Diseases
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
The purpose of this study is to assess the long term safety of SCH 420814 (preladenant) in participants with moderate to severe Parkinson's Disease who are taking an L-Dopa/dopa decarboxylase inhibitor and/or dopamine agonist.
- Conditions
- Parkinson Disease, Neurodegenerative Diseases, Central Nervous System Diseases, Movement Disorders
- Trial name
- NCT00537017
- Testing
- Preladenant, L-dopa, Other Parkinson's Disease treatments
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Alzheimer's Disease
Observational Study Of Donepezil In Routine Clinical Practice
To characterize the comorbidities and medications of patients treated with donepezil in a routine clinical practice and to verify the therapeutic response of these patients.
- Trial name
- NCT00843115
- Testing
- donepezil
- Volunteers
- 370 people
- Sponsor
- Pfizer
Progressive Supranuclear Palsy
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
This is a randomized, placebo-controlled trial of RT001 in patients with PSP.
- Trial name
- NCT04937530
- Testing
- RT001
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Biojiva LLC
Early Onset Alzheimer Disease
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)
The purpose of this study is to evaluate the efficacy of NKO™ softgels in reducing decline of global cognitive function as measured by the Neuropsychological Test Battery (NTB), in patients diagnosed with early stage Alzheimer's…
- Trial name
- MNEMOSYNE (NCT00867828)
- Testing
- Neptune Krill Oil, Fish Oil
- Where
- 14 sites in Canada
- Volunteers
- 175 people
- Sponsor
- NeuroBioPharm Inc.
Idiopathic Parkinson's Disease
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.
- Trial name
- NCT01300819
- Testing
- Rotigotine
- Where
- 87 sites in Austria, Belgium and 10 more
- Volunteers
- 349 people
- Sponsor
- UCB Pharma
Alzheimer Disease, Dementia
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Cognition Disorders
- Trial name
- SUVN-502 (NCT03564964)
- Testing
- SUVN-502
- Sponsor
- Suven Life Sciences Limited
Dementia With Lewy Bodies (DLB)
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT01278407
- Testing
- Donepezil 5 mg, Donepezil 10 mg
- Where
- 56 sites in Japan
- Volunteers
- 142 people
- Sponsor
- Eisai Co., Ltd.
Healthy Participants, Healthy Population
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants.
- Trial name
- MindStim (NCT05999916)
- Testing
- Personalized Miamind Neurostimulator
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bottneuro AG
PARKINSON DISEASE (Disorder)
A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients
Flexilev is a Parkinson's disease medicine made of small, dissolvable tablets containing low doses of levodopa and carbidopa, allowing doses to be adjusted in small, precise steps.
- Trial name
- FLORA (NCT07839793)
- Testing
- OraFID dosing device, Levodopa/Carbidopa minitablets delivered via OraFID dosing device
- Where
- 5 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Navamedic AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.